TCR diversity – a universal cancer immunotherapy biomarker?

Por McNeel, Douglas G.
Publicado no J Immunother Cancer (2016)

Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination

Por Becker, Jordan T, McNeel, Douglas G
Publicado em 2013

Immunotherapy for Prostate Cancer: False Promises or True Hope?

Por Rekoske, Brian T., McNeel, Douglas G.
Publicado no Cancer (2016)

Prostate Cancer Patients Treated with Androgen Deprivation Therapy Develop Persistent Changes in Adaptive Immune Responses

Por Morse, Matthew D., McNeel, Douglas G.
Publicado em 2010

The SSX Family of Cancer-Testis Antigens as Target Proteins for Tumor Therapy

Por Smith, Heath A., McNeel, Douglas G.
Publicado em 2010

Vaccines Targeting the Cancer Testis Antigen SSX-2 Elicit HLA-A2 Epitope-Specific Cytolytic T Cells

Por Smith, Heath A., McNeel, Douglas G.
Publicado em 2011

CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells

Por Olson, Brian M., McNeel, Douglas G.
Publicado em 2011

Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence

Por Olson, Brian M, McNeel, Douglas G
Publicado em 2012

Monitoring Regulatory Immune Responses in Tumor Immunotherapy Clinical Trials

Por Olson, Brian M., McNeel, Douglas G.
Publicado em 2013

T CELLS LOCALIZED TO THE ANDROGEN-DEPRIVED PROSTATE ARE T(H)1 AND T(H)17 BIASED

Por Morse, Matthew D., McNeel, Douglas G.
Publicado em 2011

Sipuleucel-T: immunotherapy for advanced prostate cancer

Por Olson, Brian M, McNeel, Douglas G
Publicado em 2011

SSX expression and function in prostate cancer

Por Bloom, Jordan E, McNeel, Douglas G
Publicado em 2013

B lymphocyte mediated antigen presentation of plasmid DNA

Por Colluru, Viswa Teja, McNeel, Douglas G
Publicado em 2013

SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer

Por Bloom, Jordan E., McNeel, Douglas G.
Publicado no Oncotarget (2016)

B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines

Por Colluru, Viswa Teja, McNeel, Douglas G.
Publicado no Oncotarget (2016)

Epitope optimization of a DNA vaccine targeting SSX-2 leads to PD-1 upregulation on antigen-specific CD8 T cells and PD-L1 upregulation on tumor cells

Por Rekoske, Brian, Smith, Heath A, McNeel, Douglas G
Publicado em 2013

DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses()

Por Smith, Heath A., Rekoske, Brian T., McNeel, Douglas G.
Publicado em 2014

Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses

Por Rekoske, Brian T., Olson, Brian M., McNeel, Douglas G.
Publicado no Oncoimmunology (2016)

Antibody Responses to Prostate-Associated Antigens in Patients with Prostatitis and Prostate Cancer

Por Maricque, Brett B., Eickhoff, Jens C., McNeel, Douglas G.
Publicado em 2011

Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response

Por Johnson, Laura E., Frye, Thomas P., McNeel, Douglas G.
Publicado em 2012